Preferred Label : elafibranor;
Origin ID : M000629003;
Currated CISMeF NLP mapping
- Related record
https://www.has-sante.fr/jcms/p_3576200/fr/iqirvo-elafibranor-cholangite-biliaire-primitive-cbp
2025
false
false
false
France
drug therapy, combination
evaluation of the transparency committee
cholangitis
elafibranor
Primary Biliary Cholangitis
---
https://www.ema.europa.eu/en/medicines/human/EPAR/iqirvo
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
administration, oral
elafibranor
elafibranor
orphan drug production
drug approval
europe
adult
Primary Biliary Cholangitis
drug therapy, combination
ursodeoxycholic acid
elafibranor
Peroxisome Proliferator-Activated Receptor Agonist
risk management
product surveillance, postmarketing
aged
pregnancy
breast feeding
PPAR alpha
PPAR delta
drug evaluation, preclinical
---
https://www.has-sante.fr/jcms/p_3588817/fr/iqirvo-elafibranor-cholangite-biliaire-primitive
2025
false
false
false
France
insurance, health, reimbursement
treatment outcome
administration, oral
Primary Biliary Cholangitis
drug therapy, combination
ursodeoxycholic acid
adult
elafibranor
evaluation of the transparency committee
elafibranor
---
